vTv Therapeutics Q3 net loss widens on higher R&D spending

Overview

• US biopharma firm reported Q3 net loss widened to $11.6 mln with no revenue

• Operating expenses rose yr/yr due to investment in Phase 3 CATT1 trial

• Company completed Phase 3 CATT1 trial enrollment; topline results expected mid-2027

Outlook

• Company expects topline results from Phase 3 CATT1 trial in mid 2027

• Phase 2a Hybrid CATT1 study to inform future Phase 3 research in hybrid closed-loop T1D

Result Drivers

• PHASE 3 CATT1 INVESTMENT - Co said higher R&D expenses were mainly due to continued investment in Phase 3 CATT1 trial

• HIGHER COMPENSATION COSTS - Co attributed increased G&A expenses to higher share-based compensation and payroll-related expenses

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for vTv Therapeutics Inc is $57.00, about 137.2% above its November 4 closing price of $24.03

Reuters Recommended Reads

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)